Azienda Ospedaliera Universitaria Integrata Verona — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

6 Recruiting

0 Completed trials

1 Countries active

14 Unique IMPs

N/A Results reported

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 3 Phase IV: 3

Top indications

Cystic fibrosis 2 Progressive multiple sclerosis 2 Parkinson's disease 1 Muscle spasticity 1

Top IMPs

SIPONIMOD 2 CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS 1 NIVOLUMAB 1 OZANIMOD 1 SAFINAMIDE 1 SIPONIMOD FUMARIC ACID 1 TAMOXIFEN 1 TEICOPLANIN 1

All trials

8 total

Exploratory study to evaluate the safety and tolerability of tamoxifen citrate in the treatment of cystic fibrosis in patients without mutat… Pending

2024-519657-11-00 Phase II 1 country TAMOXIFEN
EFFECTS OF SAFINAMIDE VERSUS PLACEBO ON PAIN IN PATIENTS WITH PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS: A RANDOMIZED, CONTROLLED, DOUBLE-… Pending

2025-521512-20-00 Phase III 1 country SAFINAMIDE
An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa… Recruiting

2024-517820-21-00 Phase II 1 country TEICOPLANIN
Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study Recruiting

2024-518859-27-00 Phase IV 1 country OZANIMOD
Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis Recruiting

2024-512283-65-00 Phase IV 1 country SIPONIMOD
Prospective, open-label, non-randomized, single-arm, dose titration study to investigate the efficacy and safety of IncobotulinumtoxinA in c… Recruiting

2024-518447-38-00 Phase II 1 country CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: … Recruiting

2024-515981-14-00 Phase III 1 country NIVOLUMAB
Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis Recruiting

2024-518374-13-00 Phase IV 1 country SIPONIMOD; SIPONIMOD FUMARIC ACID

Showing 1–8 of 8 trials

← All sponsors A–Z